Melola Discovery

← Melola Discovery

Akses terbuka Jurnal SINTA 1

Plasma Galectin-3 as a Predictor of Cardiac Dysfunction in Patients Undergoing Doxorubicin Chemotherapy: A Prospective Cohort Study

ACTA MEDICA INDONESIANA · Vol. 58 No. 3 (2026)

ISSN
2338-2732, 0125-9326
Terbit
2026-09-28
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng
Lisensi
creativecommons.org/licenses/by/4.0

Abstrak

Background: Doxorubicin is widely used in chemotherapy in oncology. However, it is associated with dose-dependent cardiotoxicity. Thus, early detection of cardiac dysfunction is crucial to preventing heart failure. This study aimed to evaluate plasma Galectin-3 levels, a biomarker of fibrosis and inflammation, as a predictive biomarker of cardiac dysfunction in cancer patients receiving doxorubicin chemotherapy. Methods: This observational prospective cohort study was conducted from June 2024 to February 2025 at the Integrated Cardiac Service of Cipto Mangunkusumo National General Hospital (RSCM) and Dharmais Cancer Hospital in Jakarta. Fifty-five patients completed plasma Galectin-3 and echocardiographic assessments at three time points: pre-chemotherapy, post-chemotherapy cycle 2, and post-cycle 4. Cardiac dysfunction was defined by a decrease in LVEF ≥ 10% or a GLS reduction ≥ 15%. Results: No cardiac dysfunction was observed pre-chemotherapy, but 34.5% and 50.9% of patients developed dysfunction after cycles 2 and 4, respectively. Galectin-3 levels increased significantly post-cycle 4 (mean: 46.89 ± 18.34 ng/mL; p < 0.05). Receiver operating characteristic analysis showed that post-cycle 4 Galectin-3 levels predicted cardiac dysfunction with an area under the curve of 0.767 (95% CI: 0.638–0.897; p = 0.001), 92.9% sensitivity, and 59.3% specificity at a cut-off of ≥ 37.28 ng/mL. Significant correlations were observed between Galectin-3 and GLS (r = 0.54; p = 0.00) but not LVEF. Conclusion: Plasma Galectin-3 levels, particularly after chemotherapy cycle 4, are sensitive biomarkers for detecting cardiac dysfunction in patients receiving doxorubicin. Integrating Galectin-3 with GLS may provide better detection of subclinical cardiotoxicity. Additionally, monitoring Galectin-3 levels may help identify high-risk patients requiring cardioprotective strategies

Kata kunci

Jaringan kolaborasi para penulis

40 penulis · 275 tautan kepenulisan bersama · menampilkan 40 yang paling banyak terhubung

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Institut Agama Islam Negeri Bone
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Siti SetiatiAfiliasi tidak diketahui13
Idrus AlwiAfiliasi tidak diketahui9
Rudi PutrantoAfiliasi tidak diketahui8
Evy YunihastutiAfiliasi tidak diketahui8
Noto DwimartutieAfiliasi tidak diketahui7
Sally Aman NasutionAfiliasi tidak diketahui7
Hamzah ShatriAfiliasi tidak diketahui6
Simon SalimAfiliasi tidak diketahui5
Muhammad YaminInstitut Agama Islam Negeri Bone5
Roza MulyanaAfiliasi tidak diketahui4
Eka Dian SafitriAfiliasi tidak diketahui4
Rahmi IstantiAfiliasi tidak diketahui4
Lugyanti SukrismanAfiliasi tidak diketahui4
Suzanna ImmanuelAfiliasi tidak diketahui4
Aida LydiaAfiliasi tidak diketahui4
Taufik IndrajayaAfiliasi tidak diketahui4
Arif MansjoerAfiliasi tidak diketahui4
Ceva Wicaksono PitoyoAfiliasi tidak diketahui4
Yulianto YuliantoAfiliasi tidak diketahui3
Imam SubektiAfiliasi tidak diketahui3
Respati W RanakusumaAfiliasi tidak diketahui3
Siti Rizny F SaldiAfiliasi tidak diketahui3
Jessica MarsigitAfiliasi tidak diketahui3
Suhendro SuwartoAfiliasi tidak diketahui3
Sri SunartiAfiliasi tidak diketahui3
Rensa RensaAfiliasi tidak diketahui3
Muhammad Khifzhon AzwarAfiliasi tidak diketahui3
Fatichati BudiningsihAfiliasi tidak diketahui3
Lazuardhi DwipaAfiliasi tidak diketahui3
Agus SudarsoAfiliasi tidak diketahui3
Ikhwan RinaldiAfiliasi tidak diketahui3
Iris RengganisAfiliasi tidak diketahui3
Pringgodigdo NugrohoAfiliasi tidak diketahui3
Cleopas Martin RumendeAfiliasi tidak diketahui3
Sukamto KoesnoeAfiliasi tidak diketahui3
Ni Made HustriniAfiliasi tidak diketahui3

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc) 
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Plasma Galectin-3 as a Predictor of Cardiac Dysfunction in Patients Undergoing Doxorubicin Chemotherapy:  A Prospective Cohort Study</dc:title>
	<dc:creator>Sjam, Mohammad Bhukkar Adil </dc:creator>
	<dc:creator>Ginanjar, Eka</dc:creator>
	<dc:creator>Rachman, Andhika </dc:creator>
	<dc:creator>Harimurti, Kuntjoro </dc:creator>
	<dc:subject xml:lang="en-US">Galectin-3</dc:subject>
	<dc:subject xml:lang="en-US">cardiotoxicity</dc:subject>
	<dc:subject xml:lang="en-US">Doxorubicin</dc:subject>
	<dc:subject xml:lang="en-US">Cardiac dysfunction</dc:subject>
	<dc:subject xml:lang="en-US">echocardiography</dc:subject>
	<dc:subject xml:lang="en-US">global longitudinal strain (GLS)</dc:subject>
	<dc:description xml:lang="en-US">Background: Doxorubicin is widely used in chemotherapy in oncology. However, it is associated with dose-dependent cardiotoxicity. Thus, early detection of cardiac dysfunction is crucial to preventing heart failure. This study aimed to evaluate plasma Galectin-3 levels, a biomarker of fibrosis and inflammation, as a predictive biomarker of cardiac dysfunction in cancer patients receiving doxorubicin chemotherapy. Methods: This observational prospective cohort study was conducted from June 2024 to February 2025 at the Integrated Cardiac Service of Cipto Mangunkusumo National General Hospital (RSCM) and Dharmais Cancer Hospital in Jakarta. Fifty-five patients completed plasma Galectin-3 and echocardiographic assessments at three time points: pre-chemotherapy, post-chemotherapy cycle 2, and post-cycle 4. Cardiac dysfunction was defined by a decrease in LVEF ≥ 10% or a GLS reduction ≥ 15%. Results: No cardiac dysfunction was observed pre-chemotherapy, but 34.5% and 50.9% of patients developed dysfunction after cycles 2 and 4, respectively. Galectin-3 levels increased significantly post-cycle 4 (mean: 46.89 ± 18.34 ng/mL; p &amp;lt; 0.05). Receiver operating characteristic analysis showed that post-cycle 4 Galectin-3 levels predicted cardiac dysfunction with an area under the curve of 0.767 (95% CI: 0.638–0.897; p = 0.001), 92.9% sensitivity, and 59.3% specificity at a cut-off of ≥ 37.28 ng/mL. Significant correlations were observed between Galectin-3 and GLS (r = 0.54; p = 0.00) but not LVEF. Conclusion: Plasma Galectin-3 levels, particularly after chemotherapy cycle 4, are sensitive biomarkers for detecting cardiac dysfunction in patients receiving doxorubicin. Integrating Galectin-3 with GLS may provide better detection of subclinical cardiotoxicity. Additionally, monitoring Galectin-3 levels may help identify high-risk patients requiring cardioprotective strategies</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2026-09-28</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/3070</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 58 No. 3 (2026): Acta Medica Indonesiana; 354</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/3070/884</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2026 Mohd Bhukkar Adil  Sjam, Eka Ginanjar, Andhika  Rachman, Kuntjoro  Harimurti</dc:rights>
	<dc:rights xml:lang="en-US">https://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>